Impact of Supraphysiological Estradiol Serum Levels on Birth Weight in Singletons Born After Fresh Embryo Transfer.


Journal

Reproductive sciences (Thousand Oaks, Calif.)
ISSN: 1933-7205
Titre abrégé: Reprod Sci
Pays: United States
ID NLM: 101291249

Informations de publication

Date de publication:
09 2020
Historique:
received: 20 10 2019
accepted: 21 01 2020
pubmed: 20 2 2020
medline: 19 12 2020
entrez: 20 2 2020
Statut: ppublish

Résumé

In assisted reproductive technology, high estradiol (E2) levels at trigger may increase the risk of low birth weight (LBW). Our objective was to investigate the impact of supra-physiological E2 levels at trigger, on the rate of LBW in singleton pregnancies following fresh embryo transfers (ET), in a center that typically employs the 'freeze-all' strategy in case of high E2 levels, to prevent ovarian hyper stimulation syndrome risk. A cohort study was conducted in a university hospital between November 2012 and January 2017. The main inclusion criterion was having a live birth (LB) singleton (≥ 24 weeks of gestation) after a fresh-ET. Four groups were defined according to the E2 level at trigger, as quartiles of the entire patient population. The main measured outcome was the rate of LBW. 497 fresh-ET led to LB. Mean E2 level was 1608.4 ± 945.5 pg/ml. The groups were allocated as follows: 124LB in the Group E2 < 25 percentile(p) (1106.5 pg/ml), 124LB in the Group E2 [25p-50p] (1106.5-1439 pg/ml), 124LB in the Group E2[50p-75p] (1440-1915 pg/ml), and 125LB in the Group E2 > 75p (>1915 pg/ml). There was no significant difference in the rate of LBW (Group E2 < 25p, n = 8/124, (6.5%); Group E2[25p-50p], n = 15/124, (12.1%); Group E2 [50p-75p], n = 13/124, (10.4%); and Group E2 > 75p, n = 10/12, (8.1%); (p = 0.43)). After multivariate analysis, E2 level at trigger was not significantly correlated to the rate of LBW. In our cohort, E2 level on the day of hCG trigger was not associated with increased odds of LBW after fresh embryo transfers.

Identifiants

pubmed: 32072604
doi: 10.1007/s43032-020-00174-x
pii: 10.1007/s43032-020-00174-x
doi:

Substances chimiques

Estradiol 4TI98Z838E

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1770-1777

Auteurs

Mathilde Bourdon (M)

Département de Gynécologie Obsétrique II et Médecine de la Reproduction, Université de Paris, Faculté de Médecine, AP-HP-Centre Université de Paris, Hôpital Cochin, 123 boulevard de Port-Royal, 75014, Paris, France.
Département 3I « Infection, Immunité et inflammation, Institut Cochin, INSERM U1016, Université de Paris, Paris, France.

Marion Ouazana (M)

Département de Gynécologie Obsétrique II et Médecine de la Reproduction, Université de Paris, Faculté de Médecine, AP-HP-Centre Université de Paris, Hôpital Cochin, 123 boulevard de Port-Royal, 75014, Paris, France.

Chloé Maignien (C)

Département de Gynécologie Obsétrique II et Médecine de la Reproduction, Université de Paris, Faculté de Médecine, AP-HP-Centre Université de Paris, Hôpital Cochin, 123 boulevard de Port-Royal, 75014, Paris, France.

Khaled Pocate-Cheriet (K)

Département 3I « Infection, Immunité et inflammation, Institut Cochin, INSERM U1016, Université de Paris, Paris, France.
Departement d'histologie, embryologie et biologie de la reproduction, Université de Paris, Faculté de Médecine, AP-HP-Centre Université de Paris, Hôpital Cochin, Paris, France.

Catherine Patrat (C)

Departement d'histologie, embryologie et biologie de la reproduction, Université de Paris, Faculté de Médecine, AP-HP-Centre Université de Paris, Hôpital Cochin, Paris, France.

Louis Marcellin (L)

Département de Gynécologie Obsétrique II et Médecine de la Reproduction, Université de Paris, Faculté de Médecine, AP-HP-Centre Université de Paris, Hôpital Cochin, 123 boulevard de Port-Royal, 75014, Paris, France.
Département 3I « Infection, Immunité et inflammation, Institut Cochin, INSERM U1016, Université de Paris, Paris, France.
Department "Development, Reproduction and Cancer", Institut Cochin, INSERM U1016 (Doctor Vaiman), Université de Paris, Paris, France.

Charles Chapron (C)

Département de Gynécologie Obsétrique II et Médecine de la Reproduction, Université de Paris, Faculté de Médecine, AP-HP-Centre Université de Paris, Hôpital Cochin, 123 boulevard de Port-Royal, 75014, Paris, France.
Département 3I « Infection, Immunité et inflammation, Institut Cochin, INSERM U1016, Université de Paris, Paris, France.
Department "Development, Reproduction and Cancer", Institut Cochin, INSERM U1016 (Doctor Vaiman), Université de Paris, Paris, France.

Pietro Santulli (P)

Département de Gynécologie Obsétrique II et Médecine de la Reproduction, Université de Paris, Faculté de Médecine, AP-HP-Centre Université de Paris, Hôpital Cochin, 123 boulevard de Port-Royal, 75014, Paris, France. pietrosantulli@hotmail.com.
Département 3I « Infection, Immunité et inflammation, Institut Cochin, INSERM U1016, Université de Paris, Paris, France. pietrosantulli@hotmail.com.
Department "Development, Reproduction and Cancer", Institut Cochin, INSERM U1016 (Doctor Vaiman), Université de Paris, Paris, France. pietrosantulli@hotmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH